Navigation Links
Repligen Reports Second Quarter Fiscal Year 2009 Financial Results
Date:11/6/2008

signation by the FDA, a process designed to facilitate the development and expedite the review of drugs that treat serious diseases and fill an unmet medical need. There are more than 300,000 procedures conducted in the United States and Europe each year that may benefit from enhancement with RG1068.

RG2417 for Bipolar Disorder

We have initiated a Phase 2b clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression. This is a multi-center, randomized, double-blind, placebo-controlled clinical trial in which approximately 150 patients with bipolar depression will receive either RG2417 or a placebo twice a day for eight weeks. This study is designed to assess the efficacy and safety of RG2417 on the symptoms of depression as measured by the Montgomery-Asberg Depression Rating Scale (MADRS) and the Clinical Global Impression of Change in Bipolar Disorder scale (CGI-BP-C). This study is based on the positive results of a Phase 2a study in which 83 patients received either RG2417 or a placebo twice a day for six weeks. Over the six- week treatment period, the study demonstrated a statistically significant improvement in the symptoms of depression in the patients receiving RG2417 when compared to placebo on the MADRS (p=0.01) and the CGI-BP-C (p=0.04).

HDAC Inhibitors for Friedreich's Ataxia and Huntington's Disease

We are currently developing inhibitors of histone deacetylases (HDACs) which may have utility in treating progressive, inherited neurodegenerative diseases such as Friedreich's ataxia and Huntington's disease. We have identified several potential clinical candidates and are further characterizing these leads in animal models for their pharmacologic, toxicologic and pharmacodynamic profiles. Repligen announced receipt of a $1 million research grant from the Muscular Dystrophy Association and a $125,000 grant from the Friedreich's Ataxia Research Alliance and the National Ataxia Foundation. The grants
'/>"/>

SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder
2. Repligen Announces Conference Call of Second Quarter Fiscal Year 2009 Results Thursday, November 6th, 10:00 a.m. EST
3. Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors
4. Repligen Announces Share Repurchase Program
5. Repligen Announces Conference Call to Update Orencia(R) Lawsuit
6. Repligen Elects Earl Henry, M.D. to the Board of Directors
7. Repligen to Present at Upcoming Healthcare Conferences Wednesday, November 28th and Wednesday, December 5th
8. Repligen Reports Second Quarter Fiscal Year 2008 Financial Results
9. Stereotaxis Reports Third Quarter 2008 Financial Results
10. Volcano Reports 40 Percent Growth in Quarterly Revenues
11. Dialysis Corporation of America Reports Third Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Angeles, CA (PRWEB) December 22, 2014 ... reputable PALS, BLS and ACLS online certification provider, are ... http://www.acls-pals-bls.com . The updated site now features a ... easier than ever to use. , As a ... peoples’ information is now consolidated into a single page ...
(Date:12/22/2014)... U.S. and state health officials are investigating a listeria ... least four people and sickened 28 others in 10 ... prepackaged caramel apples until more information becomes available, the ... a news release. As of Dec. 18, a ... outbreak strains of the bacteria Listeria monocytogenes . ...
(Date:12/22/2014)... 22, 2014 Super Saturday, the last ... year as the busiest day in the 2014 holiday ... Grass Station had a steady pre-Christmas stream of customers, ... past Saturday. , “I definitely intend to take advantage…of ... Denver resident who was enjoying The Grass Station’s holiday ...
(Date:12/22/2014)... recognition of Veteran’s Day, Discount Labels contributed a portion ... that provides services to veterans and their families, free ... hundred acres in the hills of Southern Indiana, the ... hiking, horseback riding, 4-wheeling, skeet shooting, and much more. ... U.S. Service men and women, police officers, fire fighters ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 7,178 small ... bustle of Black Friday shopping and opted instead to ... marketing education company, for their 5th annual “Black Friday ... charged just $7 to attend the 5 hour online ... they promptly donated to support two Central Texas based ...
Breaking Medicine News(10 mins):Health News:ACLS Online Certification Website ACLS-PALS-BLS.com Now Features a New and User-Friendly Layout 2Health News:CDC Warns of Listeria Danger From Caramel Apples 2Health News:Customers at Colorado’s Grass Station Say They’re Enjoying the Experience of Legally Purchasing Marijuana this Year to Give as Christmas Presents to Friends and Family 2Health News:Discount Labels Donates Portion of November Sales to Hero Reward Program 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 3
... as Fully as Possible , ALEXANDRIA, Va., March 3 ... all people to know that hospice delivers the highest ... who are coping with life-limiting illness. A recent article ... Quandary," by Greg Bluestein, 03/02/09) carries a misinformed quote ...
... BOSTON, March 3 Solos Endoscopy, Inc. (Pink Sheets: ... completed a Food and Drug Administration (FDA) Level II ... for the inspection. It is standard for the FDA ... and the successful inspection by the FDA validates the ...
... and non-alcoholic steatohepatitis (NASH) are well-recognized causes ... and hepatocellular carcinoma. To date, no therapy ... conditions and no approved therapeutic options are ... plays a central role in insulin resistance ...
... chronic liver inflammation of unknown etiology that is characterized ... tissue damage. In the past few years, the understanding ... that, in a genetically predisposed individual, certain agents such ... self-induced liver damage. , Dr. Waleed K Al-Hamoudi ...
... 3 NuVasive, Inc. (Nasdaq: NUVA ), ... minimally disruptive surgical treatments for the spine, announced today ... Kevin O,Boyle, Executive Vice President & Chief Financial Officer, ... Healthcare Conference at Loews Miami Beach Hotel in Miami ...
... -- China Sky One,Medical, Inc. ("China Sky One ... ), a,leading fully integrated pharmaceutical company producing over-the-counter,drugs ... announced that it,obtained production approval from the State ... Folinate Injection. Another two new traditional Chinese,medicines, Paeonol ...
Cached Medicine News:Health News:NHPCO Comments on Misleading Quote in Associated Press Article and Provides Helpful Information 2Health News:Solos Endoscopy, Inc. Successfully Completes FDA Inspection 2Health News:Is telmisartan effective in treating non-alcoholic steatohepatitis? 2Health News:Is telmisartan effective in treating non-alcoholic steatohepatitis? 3Health News:Varicella zoster infection causes severe autoimmune hepatitis 2Health News:NuVasive to Present at Barclays Capital Global Healthcare Conference 2Health News:NuVasive to Present at Barclays Capital Global Healthcare Conference 3Health News:China Sky One Medical Inc. Gets SFDA Approval for Calcium Folinate Injection 2Health News:China Sky One Medical Inc. Gets SFDA Approval for Calcium Folinate Injection 3
(Date:12/19/2014)...  Newport Corporation (NASDAQ: NEWP ) ... the company,s Board of Directors.  Dr. Kadia is ... of Evans Analytical Group, a leading global provider ... to companies in a wide range of industries.   ... Group, Dr. Kadia spent nine years with Life ...
(Date:12/19/2014)... , Dec. 19, 2014   Hospira, Inc. ... provider of injectable drugs and infusion technologies, today announced ... 33rd Annual Healthcare Conference on Wednesday, Jan. 14, 2015, ... is scheduled to begin at 10:30 a.m. Pacific time ... to all interested parties through a live audiocast accessible ...
(Date:12/19/2014)... CARDIFF-BY-THE-SEA, Calif. , Dec. 19, 2014 /PRNewswire/ ...  Sorrento), an oncology company developing new treatments for ... privately-held immuno-oncology company developing proprietary Neukoplast ® ... announced today that the companies have entered into ... CAR-TNK™ (pronounced as "Car-Tank") immunotherapies for the treatment ...
Breaking Medicine Technology:Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5
... 28 Pilgrim Software, Inc. , a world-leading ... and Quality Management ( ERCQM ) software ... Solutions Group, Inc., a California-based systems integration software provider. ... will deliver its products to an expanded base of ...
... Inc. announced today that it has initiated a Phase ... in normal, healthy subjects. "We are ... of AM152, a potentially novel anti-fibrotic agent.  Our first ... pharmacokinetic (PK) profile of this compound in normal healthy ...
Cached Medicine Technology:Pilgrim Software and Portford Solutions Sign Strategic Reseller Agreement 2Pilgrim Software and Portford Solutions Sign Strategic Reseller Agreement 3Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist 2
Pediatric size. Loops retract lids. Polished finish....
Open ring design with shaft angled at 45 degrees. Blunt teeth. Round knurled handle with dull finish....
Fixation ring with atraumatic teeth provides excellent stabilization and pressure on globe. Round knurled handle with dull finish....
... Designed to fixate the eye ... two-sided ring can easily be ... or smooth side on the ... to the eye to increase ...
Medicine Products: